Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

NASDAQ:GLMD opened at $0.31 on Thursday. The firm has a market capitalization of $1.57 million, a price-to-earnings ratio of -0.13 and a beta of 0.80. The business has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.38. Galmed Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $5.47.

Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report) last posted its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

See Also

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.